{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:51:53Z","timestamp":1779889913426,"version":"3.53.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Psoriasis may significantly affect the health-related quality of life (HRQoL) of patients. Clinical assessment has been combined with HRQoL scores to evaluate the ways in which cutaneous disease affects patients. Tildrakizumab is a humanized IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 and is approved for the management of moderate-to-severe plaque psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the impact of tildrakizumab treatment on the psychological symptoms experienced by patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A 36-week observational study that enrolled patients with psoriasis who initiated treatment with tildrakizumab 100\u2005mg was carried out. The Dermatology Life Quality Index (DLQI) and Skindex-16 questionnaires were administered at baseline and at weeks 12, 24 and 36. Psoriasis Area Severity Index (PASI), body surface area (BSA) involvement (%) and a visual analogue scale for pruritus (p-VAS) were also assessed at baseline and at each follow-up visit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-four patients were enrolled. Baseline mean (SD) PASI score and BSA involvement were 28.4 (5.6) and 38.8 (21.4), respectively. The mean (SD) DLQI, Skindex-16 and p-VAS scores at baseline were 26.4 (3.2), 68 (5.8) and 8.2 (SD not available for p-VAS). Clinical improvement was assessed at weeks 12 [PASI: 12.4 (4.2); BSA involvement: 16.5 (7.3)], 24 [PASI: 4.2 (2.8); BSA involvement: 6.1 (3.1)] and 36 [PASI: 3.6 (3.2); BSA involvement: 4.2 (1.37)]. Clinical improvement was accompanied by an improvement in quality of life at weeks 16 [DLQI: 15.5 (2.9); Skindex-16: 28.2 (4.2); p-VAS: 3.8], 24 [DLQI: 8.2 (1.4); Skindex-16: 16.2 (3.6); p-VAS: 2.6] and 36 [DLQI: 3.1 (2.4); Skindex-16: 9.3 (2.8); p-VAS: 2.8]. Our study also confirmed the safety of tildrakizumab in real-life settings, with no treatment discontinuation due to inefficacy or adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results confirm tildrakizumab as an effective treatment option for improving the HRQoL of patients with psoriasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae433","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T11:48:38Z","timestamp":1728906518000},"page":"544-550","source":"Crossref","is-referenced-by-count":5,"title":["Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study"],"prefix":"10.1093","volume":"50","author":[{"given":"Sara","family":"Cacciapuoti","sequence":"first","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-637X","authenticated-orcid":false,"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Section of Dermatology \u2013 Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"2025022416241405700_llae433-B1","volume-title":"Global Report on Psoriasis","author":"World Health Organization (WHO)","year":"2016"},{"key":"2025022416241405700_llae433-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"2025022416241405700_llae433-B3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2025022416241405700_llae433-B4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2025022416241405700_llae433-B5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"2025022416241405700_llae433-B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025022416241405700_llae433-B7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025022416241405700_llae433-B8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025022416241405700_llae433-B9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2025022416241405700_llae433-B10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S402183","article-title":"Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study","volume":"16","author":"Ruggiero","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025022416241405700_llae433-B11","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025022416241405700_llae433-B12","doi-asserted-by":"crossref","first-page":"2291323","DOI":"10.1080\/09546634.2023.2291323","article-title":"The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study","volume":"35","author":"Cacciapuoti","year":"2024","journal-title":"J\u00a0Dermatolog Treat"},{"key":"2025022416241405700_llae433-B13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CCID.S403294","article-title":"Efficacy and safety of tildrakizumab in a patient with chronic HBV infection","volume":"16","author":"Potestio","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025022416241405700_llae433-B14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2147\/CCID.S464326","article-title":"Effectiveness and safety of tildrakizumab in psoriasis patients who failed anti-IL17 treatment: a 28-week real-life study","volume":"17","author":"Megna","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025022416241405700_llae433-B15","article-title":"Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting","volume":"10","author":"Burlando","year":"2021","journal-title":"Drugs Context"},{"key":"2025022416241405700_llae433-B16","doi-asserted-by":"crossref","first-page":"e15941","DOI":"10.1111\/dth.15941","article-title":"Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025022416241405700_llae433-B17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1080\/14740338.2022.2160447","article-title":"Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge","volume":"21","author":"Ruggiero","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2025022416241405700_llae433-B18","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1111\/dth.15030","article-title":"Tildrakizumab: a new therapeutic option for erythrodermic psoriasis?","volume":"34","author":"Megna","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025022416241405700_llae433-B19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-2133.2012.10806.x","article-title":"Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis","volume":"166","author":"Fernandez-Pe\u00f1as","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025022416241405700_llae433-B20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"key":"2025022416241405700_llae433-B21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025022416241405700_llae433-B22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"2025022416241405700_llae433-B23","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3417","article-title":"\u201cDLQI seems to be \u2018action\u2019, and Skindex-29 seems to be \u2018emotion'\u201d: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures","volume":"100","author":"Paudyal","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025022416241405700_llae433-B24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: Psoriasis Area and Severity Index, Body Surface Area and Physician Global Assessment","volume":"26","author":"Bo\u017cek","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"2025022416241405700_llae433-B25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2340\/00015555-1237","article-title":"Patients\u2019 visual analogue scale: a useful method for assessing psoriasis severity","volume":"92","author":"Flytstr\u00f6m","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2025022416241405700_llae433-B26","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025022416241405700_llae433-B27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jdv.19229","article-title":"Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice","volume":"37","author":"Costanzo","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025022416241405700_llae433-B28","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/jcm11102801","article-title":"Sharing patient and clinician experiences of moderate-to-severe psoriasis: a nationwide Italian survey and expert opinion to explore barriers impacting upon patient wellbeing","volume":"11","author":"Prignano","year":"2022","journal-title":"J Clin Med"},{"key":"2025022416241405700_llae433-B29","doi-asserted-by":"crossref","first-page":"e15524","DOI":"10.1111\/dth.15524","article-title":"Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025022416241405700_llae433-B30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ad.2022.07.021","article-title":"Quality of life and body region affected by psoriasis: a systematic review","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"2025022416241405700_llae433-B31","doi-asserted-by":"crossref","first-page":"e15214","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther"},{"issue":"S 2","key":"2025022416241405700_llae433-B32","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025022416241405700_llae433-B33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1684\/ejd.2014.2511","article-title":"The relationship between quality of life and the severity of psoriasis in Turkey","volume":"25","author":"\u00c7akmur","year":"2015","journal-title":"Eur J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae433\/60884968\/llae433.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/544\/60884968\/llae433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/544\/60884968\/llae433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:24:37Z","timestamp":1740414277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/3\/544\/7821062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae433","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,14]]}}}